Bausch Health Announces Results of Special Meeting of Shareholders
Bausch Health (NYSE: BHC) announced that shareholders approved the Amended and Restated Shareholder Rights Plan Agreement at a special meeting held on October 7, 2025. The Rights Plan is dated April 14, 2025 and was amended and restated on August 25, 2025. The company said the final vote tabulation will be filed with the U.S. SEC on a Form 8-K and will be available on SEDAR+ and the company website.
This notice confirms shareholder ratification, and indicates the company will publicly report the detailed vote results via regulatory and company channels.
Bausch Health (NYSE: BHC) ha annunciato che gli azionisti hanno approvato il Piano sui Diritti degli Azionisti modificato e integrato in una riunione straordinaria svoltasi il 7 ottobre 2025. Il Piano sui Diritti è datato 14 aprile 2025 ed è stato modificato e integrato il 25 agosto 2025. L'azienda ha detto che il conteggio finale dei voti sarà depositato presso la SEC statunitense con un Modulo 8-K e sarà disponibile su SEDAR+ e sul sito dell'azienda.
Questo avviso conferma la ratifica da parte degli azionisti e indica che l'azienda riporterà pubblicamente i risultati dettagliati delle votazioni tramite canali regolamentari e dell'azienda.
Bausch Health (NYSE: BHC) anunció que los accionistas aprobaron el Acuerdo modificado y reiterado del Plan de Derechos de los Accionistas en una reunión extraordinaria celebrada el 7 de octubre de 2025. El Plan de Derechos está fechado el 14 de abril de 2025 y fue modificado y reiterado el 25 de agosto de 2025. La empresa dijo que la tabulación final de votos se presentará ante la SEC de EE. UU. en un Form 8-K y estará disponible en SEDAR+ y en el sitio web de la empresa.
Este aviso confirma la ratificación por parte de los accionistas y señala que la empresa informará públicamente los resultados detallados de la votación a través de canales regulatorios y de la empresa.
Bausch Health (NYSE: BHC)는 주주들이 개정 및 재진술 주주 권리 계획 합의를 2025년 10월 7일의 특별회의에서 승인했다고 발표했습니다. 권리 계획은 2025년 4월 14일에 작성되었으며 2025년 8월 25일에 개정 및 재작성되었습니다. 회사는 최종 투표 집계가 미국 SEC에 Form 8-K로 제출되고 SEDAR+ 및 회사 웹사이트에서 이용 가능해질 것이라고 말했습니다.
이 공지는 주주 의승을 확인하고, 회사가 규제 및 회사 채널을 통해 투표 결과의 상세 내용을 공개적으로 보도할 것임을 나타냅니다.
Bausch Health (NYSE: BHC) a annoncé que les actionnaires ont approuvé le Plan modifié et révisé des droits des actionnaires lors d'une réunion extraordinaire tenue le 7 octobre 2025. Le Plan des droits est daté du 14 avril 2025 et a été amendé et révisé le 25 août 2025. La société a indiqué que le décompte final des voix sera déposé auprès de la SEC américaine sous forme de Form 8-K et sera disponible sur SEDAR+ et sur le site de l'entreprise.
Cet avis confirme la ratification par les actionnaires et indique que la société publiera publiquement les résultats détaillés du vote par le biais des canaux réglementaires et de l'entreprise.
Bausch Health (NYSE: BHC) gab bekannt, dass die Aktionäre den geänderten und neu gefassten Aktionärsrechten-Plan in einer Sondersitzung am 7. Oktober 2025 genehmigt haben. Der Rights Plan ist datiert auf 14. April 2025 und wurde am 25. August 2025 geändert und neu formuliert. Das Unternehmen teilte mit, dass die endgültige Abstimmungsauszählung bei der US-SEC in einem Form 8-K eingereicht wird und auf SEDAR+ und auf der Unternehmenswebsite verfügbar sein wird.
Diese Mitteilung bestätigt die Ratifikation der Aktionäre und weist darauf hin, dass das Unternehmen die detaillierten Abstimmungsergebnisse öffentlich über regulatorische und unternehmensinterne Kanäle berichten wird.
Bausch Health (NYSE: BHC) أعلنت أن المساهمين وافقوا على اتفاق تعديل وتحديث خطة حقوق المساهمين في اجتماع خاص عُقد في 7 أكتوبر 2025. الخطة الحقوق مؤرخة في 14 أبريل 2025 وتم تعديلها وإعادة صياغتها في 25 أغسطس 2025. قالت الشركة إن فرز الأصوات النهائي سيُقدَّم إلى لجنة الأوراق المالية الأمريكية في Form 8-K وسيكون متاحاً على SEDAR+ وعلى موقع الشركة.
يشير هذا الإشعار إلى تصديق المساهمين ويشير إلى أن الشركة ستبلغ علناً عن نتائج التصويت التفصيلية عبر القنوات التنظيمية وقنوات الشركة.
Bausch Health (NYSE: BHC) 宣布，股东在于2025年10月7日举行的特别会议上批准了经修订并重新表述的股东权利计划协议。该权利计划的日期为2025年4月14日，并于2025年8月25日进行修改并重新表述。公司表示最终投票结果将通过8-K表格向美国SEC备案，并可在SEDAR+及公司网站取得。
此通知确认股东的批准，并表明公司将通过监管渠道和公司渠道公开披露投票结果的详细信息。
- Shareholders approved the Rights Plan adoption on Oct 7, 2025
- Rights Plan dated Apr 14, 2025, amended Aug 25, 2025
- Final vote tabulation to be filed on Form 8-K and posted publicly
- None.
LAVAL, QC / ACCESS Newswire / October 9, 2025 / Bausch Health Companies Inc. (the "Company") (NYSE:BHC)(TSX:BHC) today announced the results of the special meeting of shareholders held on October 7, 2025 (the "Shareholders Meeting"). At the Shareholders Meeting, shareholders of the Company approved the ratification, confirmation and approval of the adoption of the Company's Amended and Restated Shareholder Rights Plan Agreement dated April 14, 2025, as amended and restated on August 25, 2025 (the "Rights Plan Agreement"), as described in detail in the Company's Management Proxy Circular and Proxy Statement dated August 27, 2025.
The final vote tabulation for the matter voted on at the Shareholders Meeting will be reported to the U.S. Securities and Exchange Commission on a current report on Form 8-K, and such report will be made available on the Company's SEDAR+ profile, at www.sedarplus.ca, and on the Company's website at www.bauschhealth.com.
About Bausch Health
Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) is a global diversified pharmaceutical company enriching lives through our relentless drive to deliver better health care outcomes. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neurology, dermatology, medical aesthetic devices, international pharmaceuticals and eye health, through our controlling interest in Bausch + Lomb. Our ambition is to be a globally integrated healthcare company, trusted and valued by patients, HCPs, employees and investors. For more information, visit www.bauschhealth.com and connect with us on LinkedIn.
Forward-looking Statements
This news release may contain forward-looking statements within the meaning of applicable securities laws, including the Safe Harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements may generally be identified by the use of the words "will," "anticipates," "hopes," "expects," "intends," "plans," "should," "could," "would," "may," "believes," "subject to" and variations or similar expressions. These statements are neither historical facts nor assurances of future performance, are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Actual results are subject to other risks and uncertainties that relate more broadly to Bausch Health's overall business, including those more fully described in Bausch Health's most recent annual and quarterly reports and detailed from time to time in Bausch Health's other filings with the U.S. Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. The Company undertakes no obligation to update any of these forward-looking statements to reflect events, information or circumstances after the date of this news release or to reflect actual outcomes, unless required by law.
Investor Contact: | Media Contact: | |
Garen Sarafian | Katie Savastano | |
(877) 281-6642 (toll free) | (908) 569-3692 |
SOURCE: Bausch Health Companies Inc.
View the original press release on ACCESS Newswire
FAQ
What did Bausch Health shareholders vote on at the Oct 7, 2025 meeting (BHC)?
When was the Bausch Health Rights Plan originally dated and when was it amended (BHC)?
Where will BHC publish the final vote tabulation from the Oct 7, 2025 special meeting?
Does the announcement state when the Form 8-K with the vote results will be available for BHC?
How can investors access the Bausch Health shareholder meeting results for BHC?
